Literature DB >> 28149890

Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies.

Sawsan Rashdan1, David E Gerber1.   

Abstract

Year:  2016        PMID： 28149890      PMCID： PMC5233507          DOI： 10.21037/atm.2016.12.57

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  28 in total

1.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.

Authors:  Mark G Kris; Bruce E Johnson; Lynne D Berry; David J Kwiatkowski; A John Iafrate; Ignacio I Wistuba; Marileila Varella-Garcia; Wilbur A Franklin; Samuel L Aronson; Pei-Fang Su; Yu Shyr; D Ross Camidge; Lecia V Sequist; Bonnie S Glisson; Fadlo R Khuri; Edward B Garon; William Pao; Charles Rudin; Joan Schiller; Eric B Haura; Mark Socinski; Keisuke Shirai; Heidi Chen; Giuseppe Giaccone; Marc Ladanyi; Kelly Kugler; John D Minna; Paul A Bunn
Journal:  JAMA       Date:  2014-05-21       Impact factor: 56.272

2.  Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

Authors:  Robert B Lobell; Dongming Liu; Carolyn A Buser; Joseph P Davide; Elizabeth DePuy; Kelly Hamilton; Kenneth S Koblan; Yih Lee; Scott Mosser; Sherri L Motzel; James L Abbruzzese; Charles S Fuchs; Eric K Rowinsky; Eric H Rubin; Sunil Sharma; Paul J Deutsch; Kathryn E Mazina; Briggs W Morrison; Lynne Wildonger; Siu-Long Yao; Nancy E Kohl
Journal:  Mol Cancer Ther       Date:  2002-07       Impact factor: 6.261

3.  Pembrolizumab for the treatment of non-small-cell lung cancer.

Authors:  Edward B Garon; Naiyer A Rizvi; Rina Hui; Natasha Leighl; Ani S Balmanoukian; Joseph Paul Eder; Amita Patnaik; Charu Aggarwal; Matthew Gubens; Leora Horn; Enric Carcereny; Myung-Ju Ahn; Enriqueta Felip; Jong-Seok Lee; Matthew D Hellmann; Omid Hamid; Jonathan W Goldman; Jean-Charles Soria; Marisa Dolled-Filhart; Ruth Z Rutledge; Jin Zhang; Jared K Lunceford; Reshma Rangwala; Gregory M Lubiniecki; Charlotte Roach; Kenneth Emancipator; Leena Gandhi
Journal:  N Engl J Med       Date:  2015-04-19       Impact factor: 91.245

4.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Authors:  Julie Brahmer; Karen L Reckamp; Paul Baas; Lucio Crinò; Wilfried E E Eberhardt; Elena Poddubskaya; Scott Antonia; Adam Pluzanski; Everett E Vokes; Esther Holgado; David Waterhouse; Neal Ready; Justin Gainor; Osvaldo Arén Frontera; Libor Havel; Martin Steins; Marina C Garassino; Joachim G Aerts; Manuel Domine; Luis Paz-Ares; Martin Reck; Christine Baudelet; Christopher T Harbison; Brian Lestini; David R Spigel
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

5.  Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.

Authors:  Geoffrey Liu; D Cheng; K Ding; A Le Maitre; N Liu; D Patel; Z Chen; L Seymour; F A Shepherd; M S Tsao
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

6.  A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.

Authors:  Anne-Marie C Dingemans; Wouter W Mellema; Harry J M Groen; Atie van Wijk; Sjaak A Burgers; Peter W A Kunst; Erik Thunnissen; Danielle A M Heideman; Egbert F Smit
Journal:  Clin Cancer Res       Date:  2012-12-06       Impact factor: 12.531

7.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

8.  Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.

Authors:  Luis Paz-Ares; Vera Hirsh; Li Zhang; Filippo de Marinis; James Chih-Hsin Yang; Heather A Wakelee; Takashi Seto; Yi-Long Wu; Silvia Novello; Erszébet Juhász; Osvaldo Arén; Yan Sun; Thomas Schmelter; Teng Jin Ong; Carol Peña; Egbert F Smit; Tony S Mok
Journal:  J Thorac Oncol       Date:  2015-12       Impact factor: 15.609

9.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Authors:  Pasi A Jänne; Alice T Shaw; José Rodrigues Pereira; Gaëlle Jeannin; Johan Vansteenkiste; Carlos Barrios; Fabio Andre Franke; Lynda Grinsted; Victoria Zazulina; Paul Smith; Ian Smith; Lucio Crinò
Journal:  Lancet Oncol       Date:  2012-11-28       Impact factor: 41.316

Review 10.  The genetics and biology of KRAS in lung cancer.

Authors:  Peter M K Westcott; Minh D To
Journal:  Chin J Cancer       Date:  2012-07-02
View more
  5 in total

1.  Learning to Personalize from Practice: A Real World Evidence Approach of Care Plan Personalization based on Differential Patient Behavioral Responses in Care Management Records.

Authors:  Pei-Yun S Hsueh; Subhro Das; Chandramouli Maduri; Karie Kelly
Journal:  AMIA Annu Symp Proc       Date:  2018-12-05

Review 2.  Precision Oncology: The Road Ahead.

Authors:  Daniela Senft; Mark D M Leiserson; Eytan Ruppin; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2017-09-05       Impact factor: 11.951

3.  Tumor molecular profiling of NSCLC patients using next generation sequencing.

Authors:  Nikolaos Tsoulos; Eirini Papadopoulou; Vasiliki Metaxa-Mariatou; Georgios Tsaousis; Chrisoula Efstathiadou; Georgia Tounta; Aikaterini Scapeti; Eugenia Bourkoula; Pavlos Zarogoulidis; George Pentheroudakis; Stylianos Kakolyris; Ioannis Boukovinas; Pavlos Papakotoulas; Elias Athanasiadis; Theofanis Floros; Anna Koumarianou; Vasileios Barbounis; Anca Dinischiotu; George Nasioulas
Journal:  Oncol Rep       Date:  2017-10-23       Impact factor: 3.906

4.  Improving the efficiency of trials using innovative pilot designs: the next phase in the conduct and reporting of pilot and feasibility studies.

Authors:  Lehana Thabane; Gillian Lancaster
Journal:  Pilot Feasibility Stud       Date:  2017-07-06

Review 5.  A census of pathway maps in cancer systems biology.

Authors:  Brent M Kuenzi; Trey Ideker
Journal:  Nat Rev Cancer       Date:  2020-02-17       Impact factor: 60.716
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.